Who is sponsoring NCT03567863?

NCT03567863 is sponsored by Société Française d'Endoscopie Digestive.

What drugs are being tested in NCT03567863?

Interventions in NCT03567863: 20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®, 22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®.

What condition does NCT03567863 study?

NCT03567863 studies Pancreas Cancer, Pancreatic Adenocarcinoma.

Is NCT03567863 still recruiting?

NCT03567863 is currently completed. Last updated 1 October 2019.

Last reviewed 2019-10-01 · How we verify

NCT03567863: HISTOPAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles

Completed NA Last updated 1 October 2019

What this trial tests

NA trial testing 20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE® in Pancreas Cancer in 60 participants. Completed in 29 September 2019.

Timeline

24 June 2018

Primary endpoint
29 September 2019

29 September 2019

Quick facts

Lead sponsor	Société Française d'Endoscopie Digestive
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	diagnostic
Enrollment	60
Start date	24 June 2018
Primary completion	29 September 2019
Estimated completion	29 September 2019
Sites	1 location across France

Drugs / interventions tested

20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®
22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →
Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →

Sponsor

Société Française d'Endoscopie Digestive — full company profile →

Who can join

Adults 18 to 90, any sex, with Pancreas Cancer or Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter randomized prospective study Criteria for inclusion: Patients admitted for EUS-FNB of a pancreatic mass Goals of the study: To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific. Main criterion: \- Biopsy core length of target tissue obtained by needle pass Number of patients: 60 patients Duration of the study: 1 year

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Comparison of specimen quality among the standard suction, slow-pull, and wet suction techniques for EUS-FNA: A multicenter, prospective, randomized controlled trial.
Chen TY, Cao JW, Jin C, Ji Y, et al · · 2022 · cited 7× · PMID 36255027 · DOI 10.4103/eus-d-21-00163
Prospective study of EUS-guided tissue acquisition with a 20G core biopsy needle with a forward bevel for solid pancreatic mass.
Kanata R, Sasaki T, Matsuyama M, Ishigaki K, et al · · 2021 · cited 4× · PMID 33466194 · DOI 10.1097/md.0000000000024193
UEG Week 2019 Oral Presentations.
· 2019 · cited 3× · PMID 32213000 · DOI 10.1177/2050640619854670

Verify or expand the search:

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Société Française d'Endoscopie Digestive trials

Trials by the same sponsor.

NCT07343869 — Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection · not yet recruiting
NCT06594718 — Endoscopic Treatment of Zenker's Diverticulum (ZENKTUN) · not yet recruiting
NCT06535490 — Antibiotic Prophylaxis for EUS-FNA of Pancreatic Cystic Lesions · not yet recruiting
NCT05431738 — Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) · NA · recruiting
NCT04251013 — Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03567863 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Société Française d'Endoscopie Digestive
Last refreshed: 1 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03567863.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing